Yesterday, the Food and Drug Administration handed Impax Laboratories a complete response letter, or CRL, for its experimental Parkinson's disease drug Rytary. While an FDA rejection can spell doom for most stocks in the biotech space, shares of Impax only fell around 6% in intraday trading. In this video, health care analysts Max Macaluso and Brenton Flynn discuss this decision and how Impax's diversified portfolio helped to fortify the company against the bad news.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Can Impax Labs Shrug Off This Rejection? originally appeared on Fool.com.
Brenton Flynn, Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.